nodes	percent_of_prediction	percent_of_DWPC	metapath
Bortezomib—PTGS1—Thalidomide—leprosy	0.0941	0.132	CbGbCtD
Bortezomib—CYP1A1—Thalidomide—leprosy	0.0941	0.132	CbGbCtD
Bortezomib—PTGS1—Dapsone—leprosy	0.0753	0.106	CbGbCtD
Bortezomib—CYP2C8—Rifampicin—leprosy	0.0526	0.0738	CbGbCtD
Bortezomib—CYP2C19—Thalidomide—leprosy	0.0456	0.064	CbGbCtD
Bortezomib—CYP2C19—Rifampicin—leprosy	0.0441	0.062	CbGbCtD
Bortezomib—CYP2C8—Dapsone—leprosy	0.0434	0.061	CbGbCtD
Bortezomib—CYP1A2—Thalidomide—leprosy	0.0421	0.059	CbGbCtD
Bortezomib—CYP1A2—Rifampicin—leprosy	0.0407	0.0572	CbGbCtD
Bortezomib—CYP2C9—Thalidomide—leprosy	0.0379	0.0532	CbGbCtD
Bortezomib—CYP2C9—Rifampicin—leprosy	0.0367	0.0515	CbGbCtD
Bortezomib—CYP2C19—Dapsone—leprosy	0.0364	0.0511	CbGbCtD
Bortezomib—CYP2C9—Dapsone—leprosy	0.0303	0.0425	CbGbCtD
Bortezomib—CYP3A4—Rifampicin—leprosy	0.0213	0.0299	CbGbCtD
Bortezomib—CYP3A4—Dapsone—leprosy	0.0176	0.0247	CbGbCtD
Bortezomib—PSMB2—skin epidermis—leprosy	0.00596	0.0847	CbGeAlD
Bortezomib—Ichthyosis—Thalidomide—leprosy	0.00561	0.0301	CcSEcCtD
Bortezomib—Ichthyosis acquired—Thalidomide—leprosy	0.00561	0.0301	CcSEcCtD
Bortezomib—Disability—Thalidomide—leprosy	0.00515	0.0277	CcSEcCtD
Bortezomib—Toxic skin eruption—Thalidomide—leprosy	0.00445	0.0239	CcSEcCtD
Bortezomib—Periodontitis—Thalidomide—leprosy	0.00445	0.0239	CcSEcCtD
Bortezomib—Posterior reversible encephalopathy syndrome—Thalidomide—leprosy	0.00394	0.0212	CcSEcCtD
Bortezomib—SLC31A1—Metal ion SLC transporters—SLC11A1—leprosy	0.00382	0.123	CbGpPWpGaD
Bortezomib—CTSG—skin of body—leprosy	0.00345	0.0491	CbGeAlD
Bortezomib—PSMA1—skin of body—leprosy	0.00332	0.0471	CbGeAlD
Bortezomib—PSMD1—eye—leprosy	0.0032	0.0455	CbGeAlD
Bortezomib—Bronchopneumonia—Thalidomide—leprosy	0.00296	0.0159	CcSEcCtD
Bortezomib—PSMD2—eye—leprosy	0.00283	0.0403	CbGeAlD
Bortezomib—Lymphoedema—Thalidomide—leprosy	0.00265	0.0142	CcSEcCtD
Bortezomib—CTSG—tendon—leprosy	0.00263	0.0373	CbGeAlD
Bortezomib—Peritonitis—Thalidomide—leprosy	0.00256	0.0138	CcSEcCtD
Bortezomib—PSMD2—skin of body—leprosy	0.00247	0.035	CbGeAlD
Bortezomib—Leukaemia—Thalidomide—leprosy	0.0024	0.0129	CcSEcCtD
Bortezomib—Tumour lysis syndrome—Thalidomide—leprosy	0.00233	0.0125	CcSEcCtD
Bortezomib—Peripheral sensory neuropathy—Thalidomide—leprosy	0.00226	0.0122	CcSEcCtD
Bortezomib—CTSG—testis—leprosy	0.00218	0.0309	CbGeAlD
Bortezomib—PSMB1—eye—leprosy	0.00217	0.0309	CbGeAlD
Bortezomib—Septic shock—Thalidomide—leprosy	0.00214	0.0115	CcSEcCtD
Bortezomib—PSMB2—eye—leprosy	0.00212	0.0301	CbGeAlD
Bortezomib—PSMD1—tendon—leprosy	0.00212	0.0301	CbGeAlD
Bortezomib—PSMA1—testis—leprosy	0.00209	0.0297	CbGeAlD
Bortezomib—PSMA1—nervous system—leprosy	0.00205	0.0291	CbGeAlD
Bortezomib—Polyneuropathy—Thalidomide—leprosy	0.00198	0.0107	CcSEcCtD
Bortezomib—PSMB1—skin of body—leprosy	0.00189	0.0269	CbGeAlD
Bortezomib—PSMD2—tendon—leprosy	0.00188	0.0267	CbGeAlD
Bortezomib—PSMB8—tendon—leprosy	0.00187	0.0265	CbGeAlD
Bortezomib—PSMB2—skin of body—leprosy	0.00185	0.0262	CbGeAlD
Bortezomib—PSMD1—testis—leprosy	0.00175	0.0249	CbGeAlD
Bortezomib—CYP1A1—skin epidermis—leprosy	0.00175	0.0249	CbGeAlD
Bortezomib—Meningitis—Thalidomide—leprosy	0.00167	0.00896	CcSEcCtD
Bortezomib—PSMB5—tendon—leprosy	0.00165	0.0234	CbGeAlD
Bortezomib—Dementia—Thalidomide—leprosy	0.00157	0.00847	CcSEcCtD
Bortezomib—PSMD2—testis—leprosy	0.00155	0.0221	CbGeAlD
Bortezomib—Electrolyte imbalance—Thalidomide—leprosy	0.00155	0.00832	CcSEcCtD
Bortezomib—PSMB8—testis—leprosy	0.00154	0.0219	CbGeAlD
Bortezomib—PSMD2—nervous system—leprosy	0.00153	0.0217	CbGeAlD
Bortezomib—Dysaesthesia—Thalidomide—leprosy	0.00149	0.00803	CcSEcCtD
Bortezomib—Pericarditis—Thalidomide—leprosy	0.00149	0.00803	CcSEcCtD
Bortezomib—PSMB1—tendon—leprosy	0.00144	0.0205	CbGeAlD
Bortezomib—Proteinuria—Dapsone—leprosy	0.00144	0.00772	CcSEcCtD
Bortezomib—Ascites—Thalidomide—leprosy	0.00142	0.00765	CcSEcCtD
Bortezomib—Protein urine present—Dapsone—leprosy	0.00142	0.00762	CcSEcCtD
Bortezomib—PSMB2—tendon—leprosy	0.00141	0.02	CbGeAlD
Bortezomib—Hernia—Thalidomide—leprosy	0.00138	0.00741	CcSEcCtD
Bortezomib—PSMB5—testis—leprosy	0.00136	0.0194	CbGeAlD
Bortezomib—Grand mal convulsion—Thalidomide—leprosy	0.00136	0.0073	CcSEcCtD
Bortezomib—SLC31A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC11A1—leprosy	0.00129	0.0416	CbGpPWpGaD
Bortezomib—Transient ischaemic attack—Thalidomide—leprosy	0.00128	0.00688	CcSEcCtD
Bortezomib—Lymphopenia—Thalidomide—leprosy	0.00126	0.00679	CcSEcCtD
Bortezomib—SLC31A1—tendon—leprosy	0.00122	0.0173	CbGeAlD
Bortezomib—PSMB1—testis—leprosy	0.00119	0.0169	CbGeAlD
Bortezomib—PSMB1—nervous system—leprosy	0.00117	0.0166	CbGeAlD
Bortezomib—PSMB2—testis—leprosy	0.00116	0.0165	CbGeAlD
Bortezomib—PSMB2—nervous system—leprosy	0.00114	0.0162	CbGeAlD
Bortezomib—Foetor hepaticus—Thalidomide—leprosy	0.00114	0.00612	CcSEcCtD
Bortezomib—Inappropriate antidiuretic hormone secretion—Thalidomide—leprosy	0.00111	0.00598	CcSEcCtD
Bortezomib—Platelet count decreased—Thalidomide—leprosy	0.00109	0.00584	CcSEcCtD
Bortezomib—Febrile neutropenia—Thalidomide—leprosy	0.00107	0.00578	CcSEcCtD
Bortezomib—Deep vein thrombosis—Thalidomide—leprosy	0.00106	0.00571	CcSEcCtD
Bortezomib—PTGS1—blood vessel—leprosy	0.00103	0.0146	CbGeAlD
Bortezomib—Psoriasis—Thalidomide—leprosy	0.00103	0.00553	CcSEcCtD
Bortezomib—Oral candidiasis—Thalidomide—leprosy	0.00102	0.00547	CcSEcCtD
Bortezomib—Hypomagnesaemia—Thalidomide—leprosy	0.00102	0.00547	CcSEcCtD
Bortezomib—SLC31A1—testis—leprosy	0.00101	0.0143	CbGeAlD
Bortezomib—Hypothyroidism—Thalidomide—leprosy	0.00101	0.00541	CcSEcCtD
Bortezomib—Nail disorder—Thalidomide—leprosy	0.000996	0.00536	CcSEcCtD
Bortezomib—SLC31A1—nervous system—leprosy	0.000989	0.0141	CbGeAlD
Bortezomib—Intestinal obstruction—Thalidomide—leprosy	0.000948	0.0051	CcSEcCtD
Bortezomib—Liver disorder—Thalidomide—leprosy	0.000948	0.0051	CcSEcCtD
Bortezomib—Seborrhoeic dermatitis—Thalidomide—leprosy	0.000948	0.0051	CcSEcCtD
Bortezomib—PSMD1—Parkin-Ubiquitin Proteasomal System pathway—PARK2—leprosy	0.000945	0.0304	CbGpPWpGaD
Bortezomib—PSMD2—Parkin-Ubiquitin Proteasomal System pathway—PARK2—leprosy	0.00094	0.0303	CbGpPWpGaD
Bortezomib—Neuralgia—Thalidomide—leprosy	0.00093	0.005	CcSEcCtD
Bortezomib—Hypercalcaemia—Thalidomide—leprosy	0.00093	0.005	CcSEcCtD
Bortezomib—Hepatomegaly—Thalidomide—leprosy	0.000913	0.00491	CcSEcCtD
Bortezomib—Interstitial lung disease—Thalidomide—leprosy	0.000913	0.00491	CcSEcCtD
Bortezomib—Lung disorder—Thalidomide—leprosy	0.000913	0.00491	CcSEcCtD
Bortezomib—Psychotic disorder—Dapsone—leprosy	0.000895	0.00481	CcSEcCtD
Bortezomib—Neuritis—Thalidomide—leprosy	0.000865	0.00465	CcSEcCtD
Bortezomib—Cholestasis—Thalidomide—leprosy	0.000851	0.00458	CcSEcCtD
Bortezomib—Pleural effusion—Thalidomide—leprosy	0.000844	0.00454	CcSEcCtD
Bortezomib—Skin ulcer—Thalidomide—leprosy	0.00083	0.00446	CcSEcCtD
Bortezomib—Nasopharyngitis—Dapsone—leprosy	0.000819	0.00441	CcSEcCtD
Bortezomib—Muscular weakness—Dapsone—leprosy	0.000808	0.00435	CcSEcCtD
Bortezomib—Myocardial ischaemia—Thalidomide—leprosy	0.000804	0.00432	CcSEcCtD
Bortezomib—Influenza—Dapsone—leprosy	0.000792	0.00426	CcSEcCtD
Bortezomib—Petechiae—Thalidomide—leprosy	0.000785	0.00422	CcSEcCtD
Bortezomib—Endocrine disorder—Thalidomide—leprosy	0.000779	0.00419	CcSEcCtD
Bortezomib—Numbness—Thalidomide—leprosy	0.000779	0.00419	CcSEcCtD
Bortezomib—Pancreatitis—Dapsone—leprosy	0.000776	0.00417	CcSEcCtD
Bortezomib—Blood disorder—Thalidomide—leprosy	0.000774	0.00416	CcSEcCtD
Bortezomib—Acne—Thalidomide—leprosy	0.000768	0.00413	CcSEcCtD
Bortezomib—Apnoea—Thalidomide—leprosy	0.000762	0.0041	CcSEcCtD
Bortezomib—Sensory loss—Thalidomide—leprosy	0.000746	0.00401	CcSEcCtD
Bortezomib—Proteinuria—Thalidomide—leprosy	0.000735	0.00395	CcSEcCtD
Bortezomib—Protein urine present—Thalidomide—leprosy	0.000725	0.0039	CcSEcCtD
Bortezomib—Photosensitivity reaction—Dapsone—leprosy	0.000723	0.00389	CcSEcCtD
Bortezomib—Skin discolouration—Thalidomide—leprosy	0.000715	0.00385	CcSEcCtD
Bortezomib—Bone disorder—Thalidomide—leprosy	0.000715	0.00385	CcSEcCtD
Bortezomib—Viral infection—Thalidomide—leprosy	0.000715	0.00385	CcSEcCtD
Bortezomib—Cellulitis—Thalidomide—leprosy	0.000711	0.00382	CcSEcCtD
Bortezomib—Hyperbilirubinaemia—Thalidomide—leprosy	0.000711	0.00382	CcSEcCtD
Bortezomib—Hypocalcaemia—Thalidomide—leprosy	0.000706	0.0038	CcSEcCtD
Bortezomib—Oliguria—Thalidomide—leprosy	0.000701	0.00377	CcSEcCtD
Bortezomib—Herpes simplex—Thalidomide—leprosy	0.000701	0.00377	CcSEcCtD
Bortezomib—Hyperuricaemia—Thalidomide—leprosy	0.000697	0.00375	CcSEcCtD
Bortezomib—Neuropathy peripheral—Dapsone—leprosy	0.000692	0.00372	CcSEcCtD
Bortezomib—Dyskinesia—Thalidomide—leprosy	0.000688	0.0037	CcSEcCtD
Bortezomib—Leukocytosis—Thalidomide—leprosy	0.000688	0.0037	CcSEcCtD
Bortezomib—Hearing impaired—Thalidomide—leprosy	0.000679	0.00365	CcSEcCtD
Bortezomib—Bone pain—Thalidomide—leprosy	0.000674	0.00363	CcSEcCtD
Bortezomib—Atrioventricular block—Thalidomide—leprosy	0.000666	0.00358	CcSEcCtD
Bortezomib—Sinusitis—Dapsone—leprosy	0.000662	0.00356	CcSEcCtD
Bortezomib—Gait disturbance—Thalidomide—leprosy	0.000662	0.00356	CcSEcCtD
Bortezomib—Blood uric acid increased—Thalidomide—leprosy	0.000658	0.00354	CcSEcCtD
Bortezomib—Hepatocellular injury—Thalidomide—leprosy	0.000646	0.00347	CcSEcCtD
Bortezomib—Pulmonary embolism—Thalidomide—leprosy	0.000646	0.00347	CcSEcCtD
Bortezomib—Hyperkalaemia—Thalidomide—leprosy	0.000635	0.00341	CcSEcCtD
Bortezomib—Colitis—Thalidomide—leprosy	0.00062	0.00334	CcSEcCtD
Bortezomib—Candida infection—Thalidomide—leprosy	0.000617	0.00332	CcSEcCtD
Bortezomib—Neuropathy—Thalidomide—leprosy	0.000607	0.00326	CcSEcCtD
Bortezomib—Dry eye—Thalidomide—leprosy	0.000597	0.00321	CcSEcCtD
Bortezomib—Tinnitus—Dapsone—leprosy	0.000591	0.00318	CcSEcCtD
Bortezomib—Oesophagitis—Thalidomide—leprosy	0.00059	0.00317	CcSEcCtD
Bortezomib—SLC31A1—SLC-mediated transmembrane transport—SLC11A1—leprosy	0.000587	0.0189	CbGpPWpGaD
Bortezomib—Pulmonary oedema—Thalidomide—leprosy	0.000575	0.00309	CcSEcCtD
Bortezomib—Sepsis—Thalidomide—leprosy	0.000561	0.00302	CcSEcCtD
Bortezomib—Erythema—Dapsone—leprosy	0.000552	0.00297	CcSEcCtD
Bortezomib—Lymphadenopathy—Thalidomide—leprosy	0.00055	0.00296	CcSEcCtD
Bortezomib—CYP1A1—skin of body—leprosy	0.000543	0.00771	CbGeAlD
Bortezomib—Thrombophlebitis—Thalidomide—leprosy	0.000542	0.00291	CcSEcCtD
Bortezomib—Diabetes mellitus—Thalidomide—leprosy	0.000539	0.0029	CcSEcCtD
Bortezomib—Gastroenteritis—Thalidomide—leprosy	0.000529	0.00285	CcSEcCtD
Bortezomib—Vascular purpura—Thalidomide—leprosy	0.000524	0.00282	CcSEcCtD
Bortezomib—Deafness—Thalidomide—leprosy	0.000524	0.00282	CcSEcCtD
Bortezomib—Vision blurred—Dapsone—leprosy	0.00052	0.0028	CcSEcCtD
Bortezomib—Eye pain—Thalidomide—leprosy	0.00052	0.00279	CcSEcCtD
Bortezomib—Cardiac failure congestive—Thalidomide—leprosy	0.000517	0.00278	CcSEcCtD
Bortezomib—Renal failure acute—Thalidomide—leprosy	0.000508	0.00273	CcSEcCtD
Bortezomib—Libido decreased—Thalidomide—leprosy	0.000506	0.00272	CcSEcCtD
Bortezomib—Increased appetite—Thalidomide—leprosy	0.000499	0.00268	CcSEcCtD
Bortezomib—Amnesia—Thalidomide—leprosy	0.000499	0.00268	CcSEcCtD
Bortezomib—Vertigo—Dapsone—leprosy	0.000496	0.00267	CcSEcCtD
Bortezomib—Atrial fibrillation—Thalidomide—leprosy	0.000495	0.00266	CcSEcCtD
Bortezomib—Dermatitis bullous—Thalidomide—leprosy	0.000491	0.00264	CcSEcCtD
Bortezomib—Purpura—Thalidomide—leprosy	0.000487	0.00262	CcSEcCtD
Bortezomib—Arthritis—Thalidomide—leprosy	0.000483	0.0026	CcSEcCtD
Bortezomib—Cough—Dapsone—leprosy	0.000481	0.00259	CcSEcCtD
Bortezomib—Cardiac failure—Thalidomide—leprosy	0.000481	0.00258	CcSEcCtD
Bortezomib—Lethargy—Thalidomide—leprosy	0.000479	0.00257	CcSEcCtD
Bortezomib—PTGS1—skin of body—leprosy	0.000477	0.00678	CbGeAlD
Bortezomib—Hyponatraemia—Thalidomide—leprosy	0.000471	0.00253	CcSEcCtD
Bortezomib—Pain in extremity—Thalidomide—leprosy	0.000469	0.00252	CcSEcCtD
Bortezomib—Gastrointestinal haemorrhage—Thalidomide—leprosy	0.000469	0.00252	CcSEcCtD
Bortezomib—Diplopia—Thalidomide—leprosy	0.000469	0.00252	CcSEcCtD
Bortezomib—Osteoarthritis—Thalidomide—leprosy	0.000469	0.00252	CcSEcCtD
Bortezomib—Disturbance in sexual arousal—Thalidomide—leprosy	0.000465	0.0025	CcSEcCtD
Bortezomib—Migraine—Thalidomide—leprosy	0.000462	0.00248	CcSEcCtD
Bortezomib—Psychotic disorder—Thalidomide—leprosy	0.000458	0.00246	CcSEcCtD
Bortezomib—Face oedema—Thalidomide—leprosy	0.000453	0.00243	CcSEcCtD
Bortezomib—Cardiac arrest—Thalidomide—leprosy	0.000446	0.0024	CcSEcCtD
Bortezomib—Ataxia—Thalidomide—leprosy	0.000441	0.00237	CcSEcCtD
Bortezomib—Tachycardia—Dapsone—leprosy	0.000439	0.00236	CcSEcCtD
Bortezomib—Dehydration—Thalidomide—leprosy	0.000436	0.00235	CcSEcCtD
Bortezomib—Dry skin—Thalidomide—leprosy	0.00043	0.00231	CcSEcCtD
Bortezomib—Orthostatic hypotension—Thalidomide—leprosy	0.000428	0.0023	CcSEcCtD
Bortezomib—Hypokalaemia—Thalidomide—leprosy	0.000427	0.0023	CcSEcCtD
Bortezomib—Breast disorder—Thalidomide—leprosy	0.000424	0.00228	CcSEcCtD
Bortezomib—Cramp muscle—Thalidomide—leprosy	0.000422	0.00227	CcSEcCtD
Bortezomib—Toxic epidermal necrolysis—Thalidomide—leprosy	0.000422	0.00227	CcSEcCtD
Bortezomib—Muscular weakness—Thalidomide—leprosy	0.000414	0.00222	CcSEcCtD
Bortezomib—Abdominal distension—Thalidomide—leprosy	0.000408	0.00219	CcSEcCtD
Bortezomib—Insomnia—Dapsone—leprosy	0.000407	0.00219	CcSEcCtD
Bortezomib—Dysphagia—Thalidomide—leprosy	0.000405	0.00218	CcSEcCtD
Bortezomib—Influenza—Thalidomide—leprosy	0.000405	0.00218	CcSEcCtD
Bortezomib—Bronchospasm—Thalidomide—leprosy	0.000399	0.00214	CcSEcCtD
Bortezomib—Pancreatitis—Thalidomide—leprosy	0.000397	0.00214	CcSEcCtD
Bortezomib—PSMA1—Antigen processing: Ubiquitination & Proteasome degradation—PARK2—leprosy	0.000397	0.0128	CbGpPWpGaD
Bortezomib—PSMD1—Antigen processing: Ubiquitination & Proteasome degradation—PARK2—leprosy	0.000395	0.0127	CbGpPWpGaD
Bortezomib—Angina pectoris—Thalidomide—leprosy	0.000395	0.00212	CcSEcCtD
Bortezomib—PSMA1—Vpu mediated degradation of CD4—CD4—leprosy	0.000394	0.0127	CbGpPWpGaD
Bortezomib—PSMD2—Antigen processing: Ubiquitination & Proteasome degradation—PARK2—leprosy	0.000393	0.0127	CbGpPWpGaD
Bortezomib—PSMD1—Vpu mediated degradation of CD4—CD4—leprosy	0.000392	0.0126	CbGpPWpGaD
Bortezomib—PSMD2—Vpu mediated degradation of CD4—CD4—leprosy	0.000391	0.0126	CbGpPWpGaD
Bortezomib—Bronchitis—Thalidomide—leprosy	0.00039	0.0021	CcSEcCtD
Bortezomib—Pancytopenia—Thalidomide—leprosy	0.000385	0.00207	CcSEcCtD
Bortezomib—Neutropenia—Thalidomide—leprosy	0.000379	0.00204	CcSEcCtD
Bortezomib—Upper respiratory tract infection—Thalidomide—leprosy	0.000377	0.00203	CcSEcCtD
Bortezomib—Pollakiuria—Thalidomide—leprosy	0.000374	0.00201	CcSEcCtD
Bortezomib—Erectile dysfunction—Thalidomide—leprosy	0.000373	0.00201	CcSEcCtD
Bortezomib—CYP2C8—testis—leprosy	0.000371	0.00527	CbGeAlD
Bortezomib—Photosensitivity reaction—Thalidomide—leprosy	0.00037	0.00199	CcSEcCtD
Bortezomib—Weight increased—Thalidomide—leprosy	0.000369	0.00198	CcSEcCtD
Bortezomib—Gastrointestinal pain—Dapsone—leprosy	0.000368	0.00198	CcSEcCtD
Bortezomib—Weight decreased—Thalidomide—leprosy	0.000367	0.00197	CcSEcCtD
Bortezomib—Hyperglycaemia—Thalidomide—leprosy	0.000366	0.00197	CcSEcCtD
Bortezomib—Pneumonia—Thalidomide—leprosy	0.000364	0.00195	CcSEcCtD
Bortezomib—PTGS1—tendon—leprosy	0.000363	0.00516	CbGeAlD
Bortezomib—Infestation NOS—Thalidomide—leprosy	0.000361	0.00194	CcSEcCtD
Bortezomib—Infestation—Thalidomide—leprosy	0.000361	0.00194	CcSEcCtD
Bortezomib—Stevens-Johnson syndrome—Thalidomide—leprosy	0.000358	0.00193	CcSEcCtD
Bortezomib—Acute coronary syndrome—Thalidomide—leprosy	0.000356	0.00192	CcSEcCtD
Bortezomib—Body temperature increased—Dapsone—leprosy	0.000356	0.00191	CcSEcCtD
Bortezomib—Abdominal pain—Dapsone—leprosy	0.000356	0.00191	CcSEcCtD
Bortezomib—Renal failure—Thalidomide—leprosy	0.000355	0.00191	CcSEcCtD
Bortezomib—Neuropathy peripheral—Thalidomide—leprosy	0.000354	0.00191	CcSEcCtD
Bortezomib—Myocardial infarction—Thalidomide—leprosy	0.000354	0.00191	CcSEcCtD
Bortezomib—Stomatitis—Thalidomide—leprosy	0.000352	0.00189	CcSEcCtD
Bortezomib—Conjunctivitis—Thalidomide—leprosy	0.000351	0.00189	CcSEcCtD
Bortezomib—Haematuria—Thalidomide—leprosy	0.000345	0.00185	CcSEcCtD
Bortezomib—PSMA1—Proteasome Degradation—IFNG—leprosy	0.000344	0.0111	CbGpPWpGaD
Bortezomib—PSMD1—Proteasome Degradation—IFNG—leprosy	0.000342	0.011	CbGpPWpGaD
Bortezomib—Epistaxis—Thalidomide—leprosy	0.000341	0.00183	CcSEcCtD
Bortezomib—PSMA1—Class I MHC mediated antigen processing & presentation—PARK2—leprosy	0.000341	0.011	CbGpPWpGaD
Bortezomib—PSMD2—Proteasome Degradation—IFNG—leprosy	0.00034	0.011	CbGpPWpGaD
Bortezomib—Sinusitis—Thalidomide—leprosy	0.000339	0.00182	CcSEcCtD
Bortezomib—PSMD1—Class I MHC mediated antigen processing & presentation—PARK2—leprosy	0.000339	0.0109	CbGpPWpGaD
Bortezomib—PSMD2—Class I MHC mediated antigen processing & presentation—PARK2—leprosy	0.000337	0.0109	CbGpPWpGaD
Bortezomib—CYP1A1—nervous system—leprosy	0.000336	0.00477	CbGeAlD
Bortezomib—Bradycardia—Thalidomide—leprosy	0.00033	0.00178	CcSEcCtD
Bortezomib—Hepatitis—Thalidomide—leprosy	0.000324	0.00174	CcSEcCtD
Bortezomib—Hypoaesthesia—Thalidomide—leprosy	0.000323	0.00174	CcSEcCtD
Bortezomib—Urinary tract disorder—Thalidomide—leprosy	0.00032	0.00172	CcSEcCtD
Bortezomib—Oedema peripheral—Thalidomide—leprosy	0.00032	0.00172	CcSEcCtD
Bortezomib—Urethral disorder—Thalidomide—leprosy	0.000318	0.00171	CcSEcCtD
Bortezomib—Visual impairment—Thalidomide—leprosy	0.000313	0.00168	CcSEcCtD
Bortezomib—Erythema multiforme—Thalidomide—leprosy	0.000307	0.00165	CcSEcCtD
Bortezomib—Eye disorder—Thalidomide—leprosy	0.000303	0.00163	CcSEcCtD
Bortezomib—Tinnitus—Thalidomide—leprosy	0.000303	0.00163	CcSEcCtD
Bortezomib—Cardiac disorder—Thalidomide—leprosy	0.000301	0.00162	CcSEcCtD
Bortezomib—PSMB2—Antigen processing: Ubiquitination & Proteasome degradation—PARK2—leprosy	0.000301	0.00968	CbGpPWpGaD
Bortezomib—PSMB5—Antigen processing: Ubiquitination & Proteasome degradation—PARK2—leprosy	0.000301	0.00968	CbGpPWpGaD
Bortezomib—PSMB1—Antigen processing: Ubiquitination & Proteasome degradation—PARK2—leprosy	0.000301	0.00968	CbGpPWpGaD
Bortezomib—PTGS1—testis—leprosy	0.000301	0.00427	CbGeAlD
Bortezomib—PSMB5—Vpu mediated degradation of CD4—CD4—leprosy	0.000299	0.00961	CbGpPWpGaD
Bortezomib—PSMB1—Vpu mediated degradation of CD4—CD4—leprosy	0.000299	0.00961	CbGpPWpGaD
Bortezomib—PSMB2—Vpu mediated degradation of CD4—CD4—leprosy	0.000299	0.00961	CbGpPWpGaD
Bortezomib—SLC31A1—Transmembrane transport of small molecules—SLC11A1—leprosy	0.000298	0.0096	CbGpPWpGaD
Bortezomib—PSMB8—Antigen processing: Ubiquitination & Proteasome degradation—PARK2—leprosy	0.000297	0.00955	CbGpPWpGaD
Bortezomib—PTGS1—nervous system—leprosy	0.000295	0.00419	CbGeAlD
Bortezomib—PSMB8—Vpu mediated degradation of CD4—CD4—leprosy	0.000295	0.00948	CbGpPWpGaD
Bortezomib—Angiopathy—Thalidomide—leprosy	0.000294	0.00158	CcSEcCtD
Bortezomib—Immune system disorder—Thalidomide—leprosy	0.000293	0.00158	CcSEcCtD
Bortezomib—Mediastinal disorder—Thalidomide—leprosy	0.000292	0.00157	CcSEcCtD
Bortezomib—Chills—Thalidomide—leprosy	0.000291	0.00157	CcSEcCtD
Bortezomib—Arrhythmia—Thalidomide—leprosy	0.00029	0.00156	CcSEcCtD
Bortezomib—Vomiting—Dapsone—leprosy	0.000286	0.00154	CcSEcCtD
Bortezomib—Mental disorder—Thalidomide—leprosy	0.000284	0.00153	CcSEcCtD
Bortezomib—Malnutrition—Thalidomide—leprosy	0.000282	0.00152	CcSEcCtD
Bortezomib—Headache—Dapsone—leprosy	0.000282	0.00152	CcSEcCtD
Bortezomib—Flatulence—Thalidomide—leprosy	0.000278	0.0015	CcSEcCtD
Bortezomib—Dysgeusia—Thalidomide—leprosy	0.000277	0.00149	CcSEcCtD
Bortezomib—Back pain—Thalidomide—leprosy	0.000273	0.00147	CcSEcCtD
Bortezomib—Muscle spasms—Thalidomide—leprosy	0.000272	0.00146	CcSEcCtD
Bortezomib—Nausea—Dapsone—leprosy	0.000267	0.00144	CcSEcCtD
Bortezomib—Vision blurred—Thalidomide—leprosy	0.000266	0.00143	CcSEcCtD
Bortezomib—Tremor—Thalidomide—leprosy	0.000265	0.00142	CcSEcCtD
Bortezomib—Ill-defined disorder—Thalidomide—leprosy	0.000262	0.00141	CcSEcCtD
Bortezomib—Anaemia—Thalidomide—leprosy	0.000261	0.0014	CcSEcCtD
Bortezomib—PSMB5—Proteasome Degradation—IFNG—leprosy	0.00026	0.00838	CbGpPWpGaD
Bortezomib—PSMB1—Proteasome Degradation—IFNG—leprosy	0.00026	0.00838	CbGpPWpGaD
Bortezomib—PSMB2—Proteasome Degradation—IFNG—leprosy	0.00026	0.00838	CbGpPWpGaD
Bortezomib—Agitation—Thalidomide—leprosy	0.00026	0.0014	CcSEcCtD
Bortezomib—PSMB5—Class I MHC mediated antigen processing & presentation—PARK2—leprosy	0.000258	0.00831	CbGpPWpGaD
Bortezomib—PSMB1—Class I MHC mediated antigen processing & presentation—PARK2—leprosy	0.000258	0.00831	CbGpPWpGaD
Bortezomib—PSMB2—Class I MHC mediated antigen processing & presentation—PARK2—leprosy	0.000258	0.00831	CbGpPWpGaD
Bortezomib—Angioedema—Thalidomide—leprosy	0.000258	0.00139	CcSEcCtD
Bortezomib—PSMB8—Proteasome Degradation—IFNG—leprosy	0.000257	0.00826	CbGpPWpGaD
Bortezomib—Malaise—Thalidomide—leprosy	0.000255	0.00137	CcSEcCtD
Bortezomib—PSMB8—Class I MHC mediated antigen processing & presentation—PARK2—leprosy	0.000255	0.00819	CbGpPWpGaD
Bortezomib—Vertigo—Thalidomide—leprosy	0.000254	0.00136	CcSEcCtD
Bortezomib—Syncope—Thalidomide—leprosy	0.000253	0.00136	CcSEcCtD
Bortezomib—Leukopenia—Thalidomide—leprosy	0.000253	0.00136	CcSEcCtD
Bortezomib—Palpitations—Thalidomide—leprosy	0.00025	0.00134	CcSEcCtD
Bortezomib—Loss of consciousness—Thalidomide—leprosy	0.000248	0.00133	CcSEcCtD
Bortezomib—CYP2D6—testis—leprosy	0.000247	0.00351	CbGeAlD
Bortezomib—CYP3A4—nervous system—leprosy	0.000246	0.0035	CbGeAlD
Bortezomib—Cough—Thalidomide—leprosy	0.000246	0.00133	CcSEcCtD
Bortezomib—Convulsion—Thalidomide—leprosy	0.000245	0.00132	CcSEcCtD
Bortezomib—Hypertension—Thalidomide—leprosy	0.000244	0.00131	CcSEcCtD
Bortezomib—CYP2D6—nervous system—leprosy	0.000243	0.00345	CbGeAlD
Bortezomib—Chest pain—Thalidomide—leprosy	0.00024	0.00129	CcSEcCtD
Bortezomib—Myalgia—Thalidomide—leprosy	0.00024	0.00129	CcSEcCtD
Bortezomib—Arthralgia—Thalidomide—leprosy	0.00024	0.00129	CcSEcCtD
Bortezomib—Anxiety—Thalidomide—leprosy	0.00024	0.00129	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Thalidomide—leprosy	0.000239	0.00128	CcSEcCtD
Bortezomib—Discomfort—Thalidomide—leprosy	0.000238	0.00128	CcSEcCtD
Bortezomib—Confusional state—Thalidomide—leprosy	0.000232	0.00125	CcSEcCtD
Bortezomib—Oedema—Thalidomide—leprosy	0.000231	0.00124	CcSEcCtD
Bortezomib—Infection—Thalidomide—leprosy	0.000229	0.00123	CcSEcCtD
Bortezomib—PTGS1—Overview of nanoparticle effects—TNF—leprosy	0.000227	0.0073	CbGpPWpGaD
Bortezomib—Shock—Thalidomide—leprosy	0.000227	0.00122	CcSEcCtD
Bortezomib—Nervous system disorder—Thalidomide—leprosy	0.000226	0.00122	CcSEcCtD
Bortezomib—Thrombocytopenia—Thalidomide—leprosy	0.000226	0.00121	CcSEcCtD
Bortezomib—Tachycardia—Thalidomide—leprosy	0.000225	0.00121	CcSEcCtD
Bortezomib—Skin disorder—Thalidomide—leprosy	0.000224	0.0012	CcSEcCtD
Bortezomib—Hyperhidrosis—Thalidomide—leprosy	0.000223	0.0012	CcSEcCtD
Bortezomib—Anorexia—Thalidomide—leprosy	0.00022	0.00118	CcSEcCtD
Bortezomib—Hypotension—Thalidomide—leprosy	0.000215	0.00116	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Thalidomide—leprosy	0.00021	0.00113	CcSEcCtD
Bortezomib—Insomnia—Thalidomide—leprosy	0.000208	0.00112	CcSEcCtD
Bortezomib—Paraesthesia—Thalidomide—leprosy	0.000207	0.00111	CcSEcCtD
Bortezomib—Dyspnoea—Thalidomide—leprosy	0.000206	0.00111	CcSEcCtD
Bortezomib—Dyspepsia—Thalidomide—leprosy	0.000203	0.00109	CcSEcCtD
Bortezomib—Decreased appetite—Thalidomide—leprosy	0.0002	0.00108	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Thalidomide—leprosy	0.000199	0.00107	CcSEcCtD
Bortezomib—Fatigue—Thalidomide—leprosy	0.000199	0.00107	CcSEcCtD
Bortezomib—Constipation—Thalidomide—leprosy	0.000197	0.00106	CcSEcCtD
Bortezomib—Pain—Thalidomide—leprosy	0.000197	0.00106	CcSEcCtD
Bortezomib—Feeling abnormal—Thalidomide—leprosy	0.00019	0.00102	CcSEcCtD
Bortezomib—Gastrointestinal pain—Thalidomide—leprosy	0.000189	0.00101	CcSEcCtD
Bortezomib—PSMA1—Host Interactions of HIV factors—CD4—leprosy	0.000188	0.00606	CbGpPWpGaD
Bortezomib—PSMD1—Host Interactions of HIV factors—CD4—leprosy	0.000187	0.00603	CbGpPWpGaD
Bortezomib—PSMD2—Host Interactions of HIV factors—CD4—leprosy	0.000186	0.006	CbGpPWpGaD
Bortezomib—Urticaria—Thalidomide—leprosy	0.000183	0.000985	CcSEcCtD
Bortezomib—Abdominal pain—Thalidomide—leprosy	0.000182	0.00098	CcSEcCtD
Bortezomib—Body temperature increased—Thalidomide—leprosy	0.000182	0.00098	CcSEcCtD
Bortezomib—PSMB8—Cytokine Signaling in Immune system—RIPK2—leprosy	0.000171	0.00549	CbGpPWpGaD
Bortezomib—Hypersensitivity—Thalidomide—leprosy	0.00017	0.000913	CcSEcCtD
Bortezomib—PSMA1—Adaptive Immune System—PARK2—leprosy	0.000169	0.00543	CbGpPWpGaD
Bortezomib—PSMD1—Adaptive Immune System—PARK2—leprosy	0.000168	0.0054	CbGpPWpGaD
Bortezomib—PSMD2—Adaptive Immune System—PARK2—leprosy	0.000167	0.00537	CbGpPWpGaD
Bortezomib—Asthenia—Thalidomide—leprosy	0.000165	0.000889	CcSEcCtD
Bortezomib—Pruritus—Thalidomide—leprosy	0.000163	0.000877	CcSEcCtD
Bortezomib—PSMD2—TNF alpha Signaling Pathway—TNF—leprosy	0.000161	0.00517	CbGpPWpGaD
Bortezomib—Diarrhoea—Thalidomide—leprosy	0.000158	0.000848	CcSEcCtD
Bortezomib—PSMB8—Interferon Signaling—HLA-DRB1—leprosy	0.000158	0.00507	CbGpPWpGaD
Bortezomib—PSMB8—Cytokine Signaling in Immune system—NOD2—leprosy	0.000155	0.00497	CbGpPWpGaD
Bortezomib—Dizziness—Thalidomide—leprosy	0.000152	0.00082	CcSEcCtD
Bortezomib—Vomiting—Thalidomide—leprosy	0.000147	0.000788	CcSEcCtD
Bortezomib—Rash—Thalidomide—leprosy	0.000145	0.000782	CcSEcCtD
Bortezomib—Dermatitis—Thalidomide—leprosy	0.000145	0.000781	CcSEcCtD
Bortezomib—Headache—Thalidomide—leprosy	0.000144	0.000777	CcSEcCtD
Bortezomib—PSMB2—Host Interactions of HIV factors—CD4—leprosy	0.000143	0.00459	CbGpPWpGaD
Bortezomib—PSMB5—Host Interactions of HIV factors—CD4—leprosy	0.000143	0.00459	CbGpPWpGaD
Bortezomib—PSMB1—Host Interactions of HIV factors—CD4—leprosy	0.000143	0.00459	CbGpPWpGaD
Bortezomib—PSMB8—Host Interactions of HIV factors—CD4—leprosy	0.000141	0.00452	CbGpPWpGaD
Bortezomib—Nausea—Thalidomide—leprosy	0.000137	0.000736	CcSEcCtD
Bortezomib—PSMB1—Adaptive Immune System—PARK2—leprosy	0.000128	0.00411	CbGpPWpGaD
Bortezomib—PSMB5—Adaptive Immune System—PARK2—leprosy	0.000128	0.00411	CbGpPWpGaD
Bortezomib—PSMB2—Adaptive Immune System—PARK2—leprosy	0.000128	0.00411	CbGpPWpGaD
Bortezomib—PSMB8—Adaptive Immune System—PARK2—leprosy	0.000126	0.00405	CbGpPWpGaD
Bortezomib—PSMA1—Adaptive Immune System—RIPK2—leprosy	0.000123	0.00395	CbGpPWpGaD
Bortezomib—PSMD1—Adaptive Immune System—RIPK2—leprosy	0.000122	0.00394	CbGpPWpGaD
Bortezomib—PSMA1—HIV Infection—CD4—leprosy	0.000122	0.00393	CbGpPWpGaD
Bortezomib—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—leprosy	0.000122	0.00392	CbGpPWpGaD
Bortezomib—PSMD2—Adaptive Immune System—RIPK2—leprosy	0.000122	0.00392	CbGpPWpGaD
Bortezomib—PSMD1—HIV Infection—CD4—leprosy	0.000122	0.00392	CbGpPWpGaD
Bortezomib—PSMD2—HIV Infection—CD4—leprosy	0.000121	0.0039	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—CYLD—leprosy	0.000116	0.00372	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—CYLD—leprosy	0.000115	0.0037	CbGpPWpGaD
Bortezomib—PSMB8—Interferon Signaling—IFNG—leprosy	0.000115	0.0037	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—CYLD—leprosy	0.000115	0.00369	CbGpPWpGaD
Bortezomib—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL2—leprosy	0.000108	0.00348	CbGpPWpGaD
Bortezomib—PSMA1—Apoptosis—TNF—leprosy	0.000107	0.00344	CbGpPWpGaD
Bortezomib—PSMD1—Apoptosis—TNF—leprosy	0.000106	0.00342	CbGpPWpGaD
Bortezomib—PSMD2—Apoptosis—TNF—leprosy	0.000106	0.00341	CbGpPWpGaD
Bortezomib—PSMB8—Cytokine Signaling in Immune system—HLA-DRB1—leprosy	0.000105	0.00339	CbGpPWpGaD
Bortezomib—PSMA1—Metabolism—SDHD—leprosy	0.000105	0.00338	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism—SDHD—leprosy	0.000105	0.00337	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—SDHD—leprosy	0.000104	0.00335	CbGpPWpGaD
Bortezomib—PTGS1—Selenium Micronutrient Network—IFNG—leprosy	0.000103	0.00331	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—PARK2—leprosy	0.000102	0.00329	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—PARK2—leprosy	0.000102	0.00327	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—PARK2—leprosy	0.000101	0.00326	CbGpPWpGaD
Bortezomib—PSMA1—Disease—SLC11A1—leprosy	9.44e-05	0.00304	CbGpPWpGaD
Bortezomib—PSMA1—Adaptive Immune System—CD40LG—leprosy	9.42e-05	0.00303	CbGpPWpGaD
Bortezomib—PSMD1—Disease—SLC11A1—leprosy	9.4e-05	0.00302	CbGpPWpGaD
Bortezomib—PSMD1—Adaptive Immune System—CD40LG—leprosy	9.38e-05	0.00302	CbGpPWpGaD
Bortezomib—PSMD2—Disease—SLC11A1—leprosy	9.35e-05	0.00301	CbGpPWpGaD
Bortezomib—PSMD2—Adaptive Immune System—CD40LG—leprosy	9.33e-05	0.003	CbGpPWpGaD
Bortezomib—PSMB5—Adaptive Immune System—RIPK2—leprosy	9.32e-05	0.003	CbGpPWpGaD
Bortezomib—PSMB1—Adaptive Immune System—RIPK2—leprosy	9.32e-05	0.003	CbGpPWpGaD
Bortezomib—PSMB2—Adaptive Immune System—RIPK2—leprosy	9.32e-05	0.003	CbGpPWpGaD
Bortezomib—PSMA1—Adaptive Immune System—CD8A—leprosy	9.32e-05	0.003	CbGpPWpGaD
Bortezomib—PSMD1—Adaptive Immune System—CD8A—leprosy	9.27e-05	0.00298	CbGpPWpGaD
Bortezomib—PSMB2—HIV Infection—CD4—leprosy	9.27e-05	0.00298	CbGpPWpGaD
Bortezomib—PSMB1—HIV Infection—CD4—leprosy	9.27e-05	0.00298	CbGpPWpGaD
Bortezomib—PSMB5—HIV Infection—CD4—leprosy	9.27e-05	0.00298	CbGpPWpGaD
Bortezomib—PSMD2—Adaptive Immune System—CD8A—leprosy	9.23e-05	0.00297	CbGpPWpGaD
Bortezomib—PSMB8—Adaptive Immune System—RIPK2—leprosy	9.18e-05	0.00295	CbGpPWpGaD
Bortezomib—PSMB8—HIV Infection—CD4—leprosy	9.14e-05	0.00294	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—CYLD—leprosy	8.77e-05	0.00282	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—CYLD—leprosy	8.77e-05	0.00282	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—CYLD—leprosy	8.77e-05	0.00282	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—CYLD—leprosy	8.64e-05	0.00278	CbGpPWpGaD
Bortezomib—PSMB2—Apoptosis—TNF—leprosy	8.1e-05	0.00261	CbGpPWpGaD
Bortezomib—PSMB1—Apoptosis—TNF—leprosy	8.1e-05	0.00261	CbGpPWpGaD
Bortezomib—PSMB5—Apoptosis—TNF—leprosy	8.1e-05	0.00261	CbGpPWpGaD
Bortezomib—PSMB8—Apoptosis—TNF—leprosy	7.98e-05	0.00257	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—SDHD—leprosy	7.97e-05	0.00257	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—SDHD—leprosy	7.97e-05	0.00257	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—SDHD—leprosy	7.97e-05	0.00257	CbGpPWpGaD
Bortezomib—CYP1A1—Aryl Hydrocarbon Receptor—TNF—leprosy	7.88e-05	0.00254	CbGpPWpGaD
Bortezomib—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—leprosy	7.88e-05	0.00254	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—SDHD—leprosy	7.86e-05	0.00253	CbGpPWpGaD
Bortezomib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—leprosy	7.77e-05	0.0025	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—PARK2—leprosy	7.75e-05	0.00249	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—PARK2—leprosy	7.75e-05	0.00249	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—PARK2—leprosy	7.75e-05	0.00249	CbGpPWpGaD
Bortezomib—PSMB8—Cytokine Signaling in Immune system—IFNG—leprosy	7.69e-05	0.00247	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—PARK2—leprosy	7.64e-05	0.00246	CbGpPWpGaD
Bortezomib—PSMA1—Adaptive Immune System—HLA-DRB1—leprosy	7.59e-05	0.00244	CbGpPWpGaD
Bortezomib—PSMD1—Adaptive Immune System—HLA-DRB1—leprosy	7.55e-05	0.00243	CbGpPWpGaD
Bortezomib—PSMD2—Adaptive Immune System—HLA-DRB1—leprosy	7.51e-05	0.00242	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—RIPK2—leprosy	7.46e-05	0.0024	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—TLR2—leprosy	7.46e-05	0.0024	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—RIPK2—leprosy	7.42e-05	0.00239	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—TLR2—leprosy	7.42e-05	0.00239	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—RIPK2—leprosy	7.38e-05	0.00238	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—TLR2—leprosy	7.38e-05	0.00238	CbGpPWpGaD
Bortezomib—PSMB5—Disease—SLC11A1—leprosy	7.16e-05	0.0023	CbGpPWpGaD
Bortezomib—PSMB1—Disease—SLC11A1—leprosy	7.16e-05	0.0023	CbGpPWpGaD
Bortezomib—PSMB2—Disease—SLC11A1—leprosy	7.16e-05	0.0023	CbGpPWpGaD
Bortezomib—PSMB5—Adaptive Immune System—CD40LG—leprosy	7.14e-05	0.0023	CbGpPWpGaD
Bortezomib—PSMB2—Adaptive Immune System—CD40LG—leprosy	7.14e-05	0.0023	CbGpPWpGaD
Bortezomib—PSMB1—Adaptive Immune System—CD40LG—leprosy	7.14e-05	0.0023	CbGpPWpGaD
Bortezomib—PSMB2—Adaptive Immune System—CD8A—leprosy	7.06e-05	0.00227	CbGpPWpGaD
Bortezomib—PSMB1—Adaptive Immune System—CD8A—leprosy	7.06e-05	0.00227	CbGpPWpGaD
Bortezomib—PSMB5—Adaptive Immune System—CD8A—leprosy	7.06e-05	0.00227	CbGpPWpGaD
Bortezomib—PSMB8—Disease—SLC11A1—leprosy	7.06e-05	0.00227	CbGpPWpGaD
Bortezomib—PSMB8—Adaptive Immune System—CD40LG—leprosy	7.04e-05	0.00226	CbGpPWpGaD
Bortezomib—PSMB8—Adaptive Immune System—CD8A—leprosy	6.96e-05	0.00224	CbGpPWpGaD
Bortezomib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—leprosy	6.9e-05	0.00222	CbGpPWpGaD
Bortezomib—PSMB8—Cytokine Signaling in Immune system—IL2—leprosy	6.83e-05	0.0022	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—NOD2—leprosy	6.76e-05	0.00217	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—NOD2—leprosy	6.73e-05	0.00216	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—NOD2—leprosy	6.7e-05	0.00215	CbGpPWpGaD
Bortezomib—PTGS1—Selenium Micronutrient Network—TNF—leprosy	6.66e-05	0.00214	CbGpPWpGaD
Bortezomib—PSMB5—Adaptive Immune System—HLA-DRB1—leprosy	5.75e-05	0.00185	CbGpPWpGaD
Bortezomib—PSMB1—Adaptive Immune System—HLA-DRB1—leprosy	5.75e-05	0.00185	CbGpPWpGaD
Bortezomib—PSMB2—Adaptive Immune System—HLA-DRB1—leprosy	5.75e-05	0.00185	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—CD40LG—leprosy	5.71e-05	0.00184	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—CD40LG—leprosy	5.69e-05	0.00183	CbGpPWpGaD
Bortezomib—PSMB8—Adaptive Immune System—HLA-DRB1—leprosy	5.67e-05	0.00182	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—CD40LG—leprosy	5.66e-05	0.00182	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—RIPK2—leprosy	5.65e-05	0.00182	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—RIPK2—leprosy	5.65e-05	0.00182	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—CD8A—leprosy	5.65e-05	0.00182	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—RIPK2—leprosy	5.65e-05	0.00182	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—TLR2—leprosy	5.65e-05	0.00182	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—TLR2—leprosy	5.65e-05	0.00182	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—TLR2—leprosy	5.65e-05	0.00182	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—CD8A—leprosy	5.62e-05	0.00181	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—CD8A—leprosy	5.6e-05	0.0018	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—RIPK2—leprosy	5.57e-05	0.00179	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—TLR2—leprosy	5.57e-05	0.00179	CbGpPWpGaD
Bortezomib—PSMA1—Adaptive Immune System—CD4—leprosy	5.35e-05	0.00172	CbGpPWpGaD
Bortezomib—PSMD1—Adaptive Immune System—CD4—leprosy	5.32e-05	0.00171	CbGpPWpGaD
Bortezomib—PSMD2—Adaptive Immune System—CD4—leprosy	5.3e-05	0.00171	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—NOD2—leprosy	5.12e-05	0.00165	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—NOD2—leprosy	5.12e-05	0.00165	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—NOD2—leprosy	5.12e-05	0.00165	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—NOD2—leprosy	5.05e-05	0.00162	CbGpPWpGaD
Bortezomib—CYP1A2—Aryl Hydrocarbon Receptor—TNF—leprosy	5.03e-05	0.00162	CbGpPWpGaD
Bortezomib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—leprosy	5.03e-05	0.00162	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—RIPK2—leprosy	4.82e-05	0.00155	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—RIPK2—leprosy	4.8e-05	0.00154	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—RIPK2—leprosy	4.77e-05	0.00154	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—HLA-DRB1—leprosy	4.6e-05	0.00148	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—HLA-DRB1—leprosy	4.58e-05	0.00147	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—HLA-DRB1—leprosy	4.56e-05	0.00147	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—CD40LG—leprosy	4.33e-05	0.00139	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—CD40LG—leprosy	4.33e-05	0.00139	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—CD40LG—leprosy	4.33e-05	0.00139	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—CD8A—leprosy	4.28e-05	0.00138	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—CD8A—leprosy	4.28e-05	0.00138	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—CD8A—leprosy	4.28e-05	0.00138	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—CD40LG—leprosy	4.27e-05	0.00137	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—CD8A—leprosy	4.22e-05	0.00136	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—SDHD—leprosy	4.17e-05	0.00134	CbGpPWpGaD
Bortezomib—PSMB5—Adaptive Immune System—CD4—leprosy	4.05e-05	0.0013	CbGpPWpGaD
Bortezomib—PSMB2—Adaptive Immune System—CD4—leprosy	4.05e-05	0.0013	CbGpPWpGaD
Bortezomib—PSMB1—Adaptive Immune System—CD4—leprosy	4.05e-05	0.0013	CbGpPWpGaD
Bortezomib—PSMB8—Adaptive Immune System—CD4—leprosy	4e-05	0.00129	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—RIPK2—leprosy	3.65e-05	0.00118	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—RIPK2—leprosy	3.65e-05	0.00118	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—RIPK2—leprosy	3.65e-05	0.00118	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—RIPK2—leprosy	3.6e-05	0.00116	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—HLA-DRB1—leprosy	3.49e-05	0.00112	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—HLA-DRB1—leprosy	3.49e-05	0.00112	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—HLA-DRB1—leprosy	3.49e-05	0.00112	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—HLA-DRB1—leprosy	3.44e-05	0.00111	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—IFNG—leprosy	3.36e-05	0.00108	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—IFNG—leprosy	3.34e-05	0.00108	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—IFNG—leprosy	3.33e-05	0.00107	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—CD4—leprosy	3.25e-05	0.00104	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—CD4—leprosy	3.23e-05	0.00104	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—CD4—leprosy	3.21e-05	0.00103	CbGpPWpGaD
Bortezomib—PSMA1—Disease—CD4—leprosy	3e-05	0.000964	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—IL2—leprosy	2.99e-05	0.000961	CbGpPWpGaD
Bortezomib—PSMD1—Disease—CD4—leprosy	2.98e-05	0.000959	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—IL2—leprosy	2.97e-05	0.000956	CbGpPWpGaD
Bortezomib—PSMD2—Disease—CD4—leprosy	2.97e-05	0.000955	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—IL2—leprosy	2.96e-05	0.000952	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—SDHD—leprosy	2.94e-05	0.000945	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—SDHD—leprosy	2.69e-05	0.000866	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—IFNG—leprosy	2.55e-05	0.000819	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—IFNG—leprosy	2.55e-05	0.000819	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—IFNG—leprosy	2.55e-05	0.000819	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—IFNG—leprosy	2.51e-05	0.000808	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—CD4—leprosy	2.46e-05	0.000791	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—CD4—leprosy	2.46e-05	0.000791	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—CD4—leprosy	2.46e-05	0.000791	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—CD4—leprosy	2.42e-05	0.00078	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—SDHD—leprosy	2.4e-05	0.000773	CbGpPWpGaD
Bortezomib—PSMB1—Disease—CD4—leprosy	2.27e-05	0.000731	CbGpPWpGaD
Bortezomib—PSMB5—Disease—CD4—leprosy	2.27e-05	0.000731	CbGpPWpGaD
Bortezomib—PSMB2—Disease—CD4—leprosy	2.27e-05	0.000731	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—IL2—leprosy	2.26e-05	0.000728	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—IL2—leprosy	2.26e-05	0.000728	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—IL2—leprosy	2.26e-05	0.000728	CbGpPWpGaD
Bortezomib—PSMB8—Disease—CD4—leprosy	2.24e-05	0.00072	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—IL2—leprosy	2.23e-05	0.000718	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—SDHD—leprosy	2.21e-05	0.000711	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—SDHD—leprosy	2.19e-05	0.000705	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—IL2—leprosy	1.93e-05	0.000621	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—IL2—leprosy	1.92e-05	0.000618	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—IL2—leprosy	1.91e-05	0.000615	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—SDHD—leprosy	1.87e-05	0.000602	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—IL2—leprosy	1.46e-05	0.000471	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—IL2—leprosy	1.46e-05	0.000471	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—IL2—leprosy	1.46e-05	0.000471	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—SDHD—leprosy	1.45e-05	0.000465	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—IL2—leprosy	1.44e-05	0.000464	CbGpPWpGaD
